Nipocalimab is an intravenous aglycosylated human IgG1 anti-FcRn monoclonal antibody indicated for generalized myasthenia gravis and warm autoimmune hemolytic anemia, lowering circulating IgG and pathogenic autoantibodies by blocking FcRn-mediated IgG recycling. Nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases.
- Mechanism
- Curator reviewed · 5 references
Nipocalimab is a human IgG1 monoclonal antibody that selectively binds to neonatal Fc receptor (FcRn) with high affinity at both neutral (extracellular) and acidic (intracellular) pH environments. FcRn is an endosomal IgG transporter that plays a role in recycling transcytosis of IgG. Nipocalimab blocks FcRn-mediated IgG recycling, lowering circulating IgG, including IgG autoantibodies and alloantibodies.
- Primary indication
- Nipocalimab is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.Curator reviewed · 3 structured indications
- Formula / weight
- 142000.0 Da (approximate)
- First approval
- Canada, 2025 · United States, 2025 · European Union, 2025
- Also known as
- immunoglobulin G1-lambda, anti-[Homo sapiens FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], Homo sapiens monoclonal antibody (gamma1 heavy chain Homo sapiens (1-445) · Immunoglobulin g1, anti-(human neonatal fc receptor) (human monoclonal m281 .gamma.-1 chain), disulfide with human monoclonal m281 .lambda.-chain, dimer
- Code names
- JNJ-80202135 · JNJ-86507083 · M-281
- Brand names
Resolves to
What you can answer from here — as of September 02, 2026
Which drugs share a target with Nipocalimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account